News Formal

Shares of Bausch Health, formerly Valeant, rise 3% on FDA approval of psoriasis treatment

  • 📰 CNBC
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 72%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

Shares of Bausch Health, formerly known as Valeant, rise 3% on FDA approval for psoriasis treatment

Bausch Health, formerly known as Valeant Pharmaceuticals, said Thursday that it and its dermatology business, Ortho Dermatologics received approval from the Food and Drug Administration for its DUOBRII lotion to treat plaque psoriasis.

div > div.group > p:first-child"> "With today's approval of DUOBRII, patients suffering from plaque psoriasis now have an innovative topical treatment option that uniquely combines two well-known ingredients, halobetasol propionate and tazarotene, with established safety profiles, into a single lotion featuring dual mechanisms of action," Bill Humphries, president Ortho Dermatologics, said in a statement.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Health-care stocks could rebound after their worst week of the yearHealth care's sharp drop comes as investors worry that left-leaning policy ideas like universal health coverage are gaining support.
Source: CNBC - 🏆 12. / 72 Read more »